Lataa...
Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population
INTRODUCTION: Recent years have brought a significant advance in chronic hepatitis C (CHC) treatment that includes development of direct acting antivirals (DAA). Two of them, boceprevir (BOC) and telaprevir (TVR), were first approved for treatment of patients infected with CHC genotype 1 in combinat...
Tallennettuna:
| Julkaisussa: | Clin Exp Hepatol |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Termedia Publishing House
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497430/ https://ncbi.nlm.nih.gov/pubmed/28856277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/ceh.2016.63869 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|